Patent Grant
9402809
The present invention relates to the use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.
Wet snuff is a variant of nicotine addition mainly seen in the US and Scandinavia and particularly in Sweden, where this variant is used on a daily basis by approximately 20% of men.
Although wet snuff is not implicated in the cardiovascular and lung disease morbidity and mortality caused by smoking, the content of nitrosamines poses a potential hazard for some cancer diseases. It is therefore of interest to make available to consumers a snuff-like product while minimising this potential hazard.
The vascular area at the administration route and the fact that the snuff is fixed over a long period of time gives an opportunity for both a quick and thorough uptake of nicotine over the mucosa. To develop a new medicated snuff bag—Snuff Similar—with similar nicotine effects but without the carcinogenic risks derived from the tobacco was the objective for this project. To reach other countries in Europe and worldwide, one approach would be to have a product that is more clean and more socially acceptable in its appearance. By using the white cellulose complex this could be achieved. A more socially acceptable alternative might also potentially increase usage, especially among women.
Due to the slow wetting and thereby release, migration and absorption of nicotine, nicotine release from snuff bags is incomplete in vivo. A present snuff variant on the market is “General white” (Swedish Match AB), has a loaded amount of 8.0 mg nicotine per snuff bag and an approximate in vitro release of 1.4 mg over a period of 30 minutes. The release in vivo is consequently less than 20%. This is mainly due to the low amount of saliva available to dissolve the nicotine and to the fact that the snuff bag is kept in place over the time of administration. Accordingly, in order to load as little nicotine as possible, there is a need for snuff bag compositions, which have a higher total release of nicotine. This will also imply that less nicotine is used in the method for preparation of such snuff compositions, which is also beneficial from an economic and an environmental point of view.
The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present invention.
The present invention relates to the use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject. The composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes.
In general the onset of the nicotine effect is within 5 minutes such as, e.g. within 4 minutes, within 3 minutes, within 2 minutes or within 1.5 minutes after application of composition between the lip and the teeth of a subject.
In the present context the term “nicotine-cellulose combination” is intended to denote a solid material composed of a cellulose which has sorbed (adsorbed and/or absorbed) a well-defined amount of nicotine (either as free base or as a pharmaceutically acceptable salt, complex or solvate) e.g. in voids or pores within the cellulose. The terms “nicotine-cellulose adduct” and “nicotine-cellulose carrier complex” as used herein are intended to have the same meaning as the term “nicotine-cellulose combination”. As used herein cellulose is an example of a carrier.
In WO 2004/056363 (to the same Applicant) is described such a nicotine-cellulose combination for release of nicotine. However, there is no disclosure of the use of such a material for the preparation of a snuff composition for use in the oral cavity.
Moreover, the present inventors have found that the use of such a nicotine-cellulose combination is especially suitable for use in a snuff composition as such a snuff composition, on the one hand releases nicotine relatively fast and thereby enables a fast onset of the nicotine effect, and on the other hand enables the nicotine content in the snuff composition to be completely or almost completely released after application in the oral cavity. The complete or almost complete release is also seen after encapsulating of the snuff composition in a suitable bag, pouch or membrane. The bag or pouch may be of any suitable material e.g. wowen or non-wowen fabric (e.g. cotton, fleece etc.), heat sealable non-wowen cellulose or other polymeric materials such as a synthetic, semi-synthetic or natural polymeric material as described herein. A material suitable for use must provide a semi-permeable membrane layer to prevent the powder or composition from leaving the bag or pouch during use. Suitable materials are also those that do not have a significant impact on the release of nicotine from the composition. To the best of the inventor's knowledge, the nicotine/tobacco snuff products available on the market today only releases a part of the nicotine contained in the snuff product (see the Examples herein).
The snuff is normally in the form of a bag or pouch suitable for buccal administration (e.g. to be inserted between the lip and the teeth) and the bag or pouch comprises the nicotine in the form of a nicotine-cellulose combination. In a particular interesting embodiment; the cellulose is microcrystalline cellulose having a mean particle size of about 180 μm. An example of a suitable quality is e.g. Avicel PH-200.
The snuff composition according to the present invention may also comprise one or more pharmaceutically acceptable excipients or additives that are suitable for buccal administration. Such agents include—but are not limited to—fillers, binders, wetting agents, stabilizing agents, coloring agents, surface active agents, pH adjusting agents, absorption enhancers, taste-masking agents, flavoring agents, texture-improving agents, etc.
As indicated above, in a specific embodiment of the present invention, the nicotine-cellulose combination (normally together with one or more pharmaceutically acceptable excipients or additives) is enclosed in a membrane material. The membrane may be a natural, synthetic, semi-synthetic hydrophilic or hydrophobic membrane. It may be made from one or more biocompatible and physiologically acceptable polymeric material. Examples of suitable membrane materials are cellulose acetate and derivatives thereof, carboxymethyl cellulose, polycellulose ester, other cellulose derivatives including ethylcellulose, propylcellulose, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polyvinyl acetate, polymers of methacrylates and acrylates, natural rubber, polycarbonate, polyethylene terephthalate, polyester, polyamide and nylon. Other suitable materials are mentioned herein before.
In keeping with long-standing patent law convention, the words “a” and “an” when used in the present specification in concert with the word comprising, including the claims, denote “one or more.” As used herein “another” may mean at least a second or more. Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
In one aspect, the invention relates to a snuff composition for buccal administration in the cheek pouch between the cheek and the jaw or under the lip. The composition may include tobacco.
The use of tobacco is deeply rooted in a large part of the world population. In the Scandinavian countries and in particular Sweden the use of moist snuff (snus) is very common as an alternative to smoking. Snuff is fermented and milled/grinded tobacco with a relatively large water content (40-60% w/w), normally to be used under the front upper lip of a human being.
Tobacco itself varies somewhat in nicotine content due to its natural origin. To adjust the nicotine release in moist snuff, various buffer systems may be added, e.g. carbonates. The moist snuff is either packed loosely, as bulk in a box or as single doses in small non-woven bags. A number of the filled and sealed bags are then packed in a box.
The moist snuff as a single dose has become popular due to the ease of use compared to the bulk product. The popularity of moist snuff is most probably due to its pharmacological nicotine absorption profile. The dose of nicotine and speed of absorption is approximately 10 ng per ml over 10 minutes though this may vary between brands. Measurements of plasma nicotine concentrations after a single day of moist snuff consumption also yielded levels similar to cigarette use. The kinetics are slightly slower compared to the kinetics when smoking tobacco, such as e.g. cigarettes and cigars; however, the overall amount of nicotine absorbed is higher when snuff is employed.
A snuff composition according to the invention comprises nicotine, or a pharmaceutically acceptable salt, solvate, complex, adduct, or derivative thereof, wherein—and when subjected to an in vitro dissolution test as described herein for 30 minutes about 30% or more of the total content of nicotine is released. This requirement with respect to in vitro release ensures that a sufficient amount of nicotine is rapidly available for absorption through the oral mucosa. In particular embodiments, about 35% or more such as, e.g., about 40% or more, about 42% or more, about 45% or more, about 50% or more of the total content of nicotine is released. In embodiments of particular interest, the release of nicotine is about 45% or more of the total content of nicotine within 30 minutes (in an in vitro test). Notably, the release within this period of time is about 50% or more such as, e.g., about 60% or more, about 70% or more or about 75% or more of the total content of nicotine in the snuff composition. The same applies to snuff compositions encapsulated in a polymeric membrane as described herein.
One important feature of the present invention is that the snuff composition leads to a rapid appearance of nicotine in the plasma. Accordingly, in general the in vivo uptake of nicotine 30 minutes after buccal administration corresponds to at least about 30% of the total content of nicotine in the snuff. As seen from the examples herein the snuff composition can be formulated so that the in vivo release of nicotine 30 minutes after buccal administration is higher, i.e. it corresponds to at least about 35% such as, e.g., at least about 40%, at least about 42%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70% or at least about 75% of the total content of nicotine in the snuff.
In a specific embodiment a snuff composition according to the invention comprises a carrier comprising internal voids. Such voids may at least partially comprise said nicotine. The carrier is typically insoluble in water or has a low solubility in water. Thus, it typically has a solubility in water at room temperature of less than 1% w/w.
A particular suitable carrier for use in a snuff composition of the invention is a cellulose, such as a microcrystalline cellulose (“mcc”). The cellulose may be synthetic or semi-synthetic celluloses, or it may be derived from natural celluloses. It is normally crystalline such as microcrystalline. Certain specific embodiments may also utilize other forms of carriers, in addition to or including mcc, such as but not limited to fibrous material or carbohydrates including cellulose (including hemicellulose, celluloses with different crystallinities and structures (e.g., varying structures including solid fibers, and addition or including fibers or the like in various structures such as web-like structures and/or other structures), including naturally occurring celluloses including Cladophora sp. Algae cellulose or the like), dextran, agarose, agar, pectin, alginate, xanthan, chitosan, starch (including potato starch, shoti starch) etc. or mixtures thereof. While not intended to be bound by theory, it is believed as of the time of this patent application that nicotine may interact the carrier (for example, mcc or other suitable carrier including other cellulose carriers) by absorbing into and/or adsorbing onto the carrier. Such interaction is completely or nearly completely reversible.
The microcrystalline cellulose may be selected from the group consisting of AVICEL® grades PH-100, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-300, PH-302, VIVACEL® grades 101, 102, 12, 20 and EMOCEL® grades 50M and 90M, and the like, and mixtures thereof.
Suitable carriers may also be those disclosed in WO 2004/064811, which is hereby included by reference.
More specifically, it is contemplated that a relatively high surface area may be of importance for a carrier that is suitable for use. Accordingly, the specific surface area of suitable carriers is normally at least 0.7 m2/g such as, e.g., 1 m2/g. In certain uses the specific surface area may range between about 0.7 m2/g and at least about 100 m2/g and/or may be anything within this range and/or may be any mixture of sizes within this range. For example, in certain embodiments, the surface area may be about 0.7 m2/g, about 1 m2/g, about 1.5 m2/g, about 2.0 m2/g, about 3.0 m2/g, about 5 m2/g, about 7 m2/g, about 10 m2/g, about 15 m2/g, about 20 m2/g, about 25 m2/g, about 35 m2/g, about 45 m2/g, about 50 m2/g, about 75 m2/g, about 100 m2/g and above about 100 m2/g, or combinations thereof. Such carriers having such suitable surface areas may include, but are not limited to, mcc, fibrous material or carbohydrates including cellulose (including hemicellulose, celluloses with different crystallinities and structures (e.g., varying structures including solid fibers, and addition or including fibers or the like in various structures such as web-like structures and/or other structures), including naturally occurring celluloses including Cladophora sp. Algae cellulose or the like), dextran, agarose, agar, pectin, alginate, xanthan, chitosan, starch (including potato starch, shoti starch) etc. and/or mixtures thereof.
In a specific embodiment, nicotine is sorbed on microcrystalline cellulose.
In general, the mean particle size of the carrier such as microcrystalline cellulose is one that is not too low and neither too high such as, e.g., at the most about 500 μm, at the most about 450 μm, at the most about 300 μm, or at the most about 200 μm, or from about 5 to about 500 μm, from 10 to about 500 μm, from 15 to about 500 μm, from about 20 to about 500 μm, from about 30 to about 500 μm, from about 40 to about 500 μm, from about 10 to about 400 μm, from about 20 to about 400 μm, from about 30 to about 400 μm, from about 40 to about 400 μm, from about 30 to about 300 μm, from about 40 to about 300 μm, from about 50 to about 250 μm, from about 50 to about 200 μm or from about 75 to about 200 μm. In specific embodiments the particle size used were about 100 μm. In a preferred aspect, the mean particle size is in a range of from about 15 to about 250 μm such as from about 20 to about 200 μm. In the examples herein a quality of microcrystalline cellulose having a mean particle size of 180 μm has proved to be well-suited for the present purpose.
In a preferred embodiment a snuff composition according to the invention contains nicotine as a nicotine-microcrystalline cellulose carrier complex in which said nicotine is at least partly sorbed on microcrystalline cellulose and/or is at least partially absorbed into the carrier and/or is at least partially adsorbed onto the carrier (e.g., mcc), or mixtures thereof. Such interaction is completely or nearly completely reversible
Hence, in certain specific embodiments nicotine is sorbed on microcrystalline cellulose, absorbed into the mcc and/or adsorbed onto the mcc, and/or combinations thereof.
In embodiments of the present invention, the carrier (e.g., but not limited to mcc and/or other naturally-occurring cellulose) is at least partially porous. This porosity may be due, for example but not limited to, the structure of the carrier, for example, branched, fibrous, or weblike structures may have pores. Ranges of pore sizes include but are not limited to pore volumes of about 0.01 cm3/g and include, but are not necessarily limited to pore volume ranges of from about 0.003 cm3/g or less to about 0.025 cm3/g, to about or greater than 0.60 cm3/g.
In general, the nicotine carrier complex or nicotine carrier adduct is present in a snuff composition of the invention in a concentration of at least about 2% w/w such as in a range from about 2% w/w to about 98% w/w, from about 2% to about 96% w/w, from about 2% w/w to about 95% w/w, from about 3% w/w to about 90% w/w, from about 4% w/w to about 85% w/w, from about 5% w/w to about 80% w/w, from about 5% w/w to about 75% w/w, from about 5% w/w to about 70% w/w, or from about 7.5% w/w to about 65% w/w.
In certain embodiments, the amount of nicotine sorbed, for example absorbed into and/or adsorbed onto to carrier can be up to 50% or more of the total weight of the composition. Ranges of the amount of nicotine sorbed onto the carrier in the present invention range for less than about 1% of the total weight of the composition to more than about 50% of the composition, including all amounts within this range. While applicants do not intend the invention to be bound by theory, it is believed at the time of preparing this application that the maximum amount of nicotine that can be sorbed onto and/or into the carrier, thereby affecting the amount, for example the percent nicotine by weight of the total composition (e.g., the maximum percentage) is affected by properties of the carrier, including but not limited to the structure of the carrier, the porosity of the carrier, and the surface area of the carrier.
In certain embodiments, the concentration of the nicotine carrier complex or nicotine carrier adduct in a composition of the invention is present in a concentration such as, e.g., from about 80% w/w to about 98% w/w, such as, e.g., from about 85% w/w to about 98% w/w, from about 90% w/w to about 98% w/w, from about 92% w/w to about 98% w/w, from about 93% w/w to about 97% w/w or from about 94% w/w to about 96% w/w.
In an alternative embodiment, the carrier compound is capable of forming a complex with nicotine such as, e.g., in the case that the carrier compound is an ion-exchange compound including polacrilex.
Concentrations and Amounts of Nicotine
As mentioned above, nicotine may be present in any suitable form. Normally, nicotine is selected from the group consisting of nicotine base, nicotine hydrochloride, nicotine dihydrochloride, nicotine monotartrate, nicotine bitartrate, nicotine sulfate, nicotine zinc chloride such as nicotine zinc chloride monohydrate and nicotine salicylate. In a preferred aspect, nicotine is in its free base form, which easily can be sorbed on a cellulose to form a microcrystalline cellulose-nicotine carrier complex or carrier adduct.
Normally, the nicotine compound (calculated as the free base) is present in a concentration of at least about 0.1% w/w such as in a range from about 0.1% w/w to about 50% w/w such as, e.g., from about 0.5% w/w to about 45% w/w, from about 1.0% w/w to about 40% w/w, from about 1.5% w/w to about 35% w/w, from about 2% w/w to about 30% w/w, from about 2.5% w/w to about 25% w/w, from about 2.5% w/w to about 20% w/w, from about 3% w/w to about 15% w/w.
However, in a more interesting embodiment a snuff composition according to the invention contains nicotine in a concentration from about 0.1% w/w to about 10% w/w, such as, e.g., from about from about 0.1% w/w to about 8% w/w, from about 0.1% w/w to about 6% w/w, from about 0.1% w/w to about 4% w/w, from about 0.1% w/w to about 2% w/w, from about 0.1% w/w to about 1.5% w/w, from about 0.2% w/w to about 1.0% w/w or from about 0.2% w/w to about 0.8% w/w, calculated as free base.
In a snuff composition of the invention the nicotine is typically present in a concentration from about 0.1% w/w to about 5% w/w, such as, e.g., from about from about 0.1% w/w to about 4% w/w, from about 0.1% w/w to about 3% w/w, from about 0.1% w/w to about 2% w/w, from about 0.1% w/w to about 1% w/w, from about 0.1% w/w to about 0.75% w/w, from about 0.2% w/w to about 0.5% w/w or from about 0.2% w/w to about 0.4% w/w, calculated as free base.
As mentioned above, the nicotine is present in the form of a nicotine-cellulose combination. In general, this combination is present in a concentration of from about 5% to about 100% such as, e.g., from about 10 to about 100%, from about 5% to about 50% or, alternatively, from about 45% to about 100%. The choice of suitable concentration depends on the load of nicotine in the nicotine-cellulose combination and the dosage of nicotine in a single pouch or bag. If the load is relatively high, then the concentration of the combination may be lower than if the load is relatively low. In a specific embodiment using e.g. Avicel® or a similar cellulose quality a concentration of the combination is generally from about 80% w/w to about 98% w/w, such as, e.g., from about 85% w/w to about 98% w/w, from about 90% w/w to about 98% w/w, from about 92% w/w to about 98% w/w, from about 93% w/w to about 97% w/w or from about 94% w/w to about 96% w/w.
The concentration of nicotine (or the pharmaceutically acceptable salt, complex or solvate thereof in the combination is at the most 70% w/w such as, e.g., at the most 60% w/w, at the most 50% w/w, at the most 45% w/w. The content of nicotine must not be so high that the combination (which is in powder form) “sweats”, so that nicotine desorbs, evaporates or otherwise disappears from the combination. Accordingly, the load of nicotine in the combination is dependent on the particular cellulose employed. If the surface area of the cellulose material is relatively high, then a larger amount of nicotine can be contained therein in a stable manner during a suitable period of time, whereas a cellulose having a smaller surface area normally is indicative for a lower capacity to load nicotine in a suitable manner with respect to stability.
For most cellulose qualities, the concentration of nicotine in the nicotine-cellulose combination is at the most about 45% w/w, such as, e.g., at the most about 40% w/w, at the most about 35% w/w, at the most about 30% w/w, at the most about 25% w/w, at the most about 20% w/w, at the most about 15% w/w, at the most about 12.5% w/w, at the most about 10% w/w, at the most about 9.5% w/w, at the most about 9% w/w, at the most about 8.5% w/w or at the most about 8% w/w, and the concentration being calculated as the nicotine base.
In a specific embodiment, a particulate material according to the present invention has a concentration of nicotine or the pharmaceutically acceptable salt, complex or solvate thereof in the particulate material is at the most about 7.5% w/w such as, e.g., at the most about 7% w/w, at the most about 6.5% w/w, at the most about 6% w/w, at the most about 5.5% w/w, at the most about 5% w/w, at the most about 4.5% w/w, at the most about 4% w/w, at the most about 3% w/w, at the most about 2% w/w or at the most about 1% w/w, and the concentration being calculated as the nicotine base.
The amount of the nicotine compound (calculated as the free base) in a composition of the inventions is generally from about 0.5 mg to about 10 mg such as, e.g., from about 1 mg to about 8 mg, from about 1.5 mg to about 7.5 mg, from about 2 mg to about 5 mg, from about 2.5 mg to about 5 mg, from about 3 to about 10 mg, from about 3 to about 7.5 mg or from about 3 mg to about 5 mg such as, e.g., about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 5 mg or about 6 mg, as calculated as free nicotine base. In particular a dosage of 2 mg, 3 mg, 4 mg and 6 mg is of commercial interest.
Buffering Agents
A composition according to the invention may also contain one or more buffering agents. It is generally known that a slightly alkaline reaction (between 7 and 8) in the oral cavity enhances the absorption of nicotine. Accordingly, it may be and advantage to incorporate a buffer substance in the composition such that a slightly alkaline reaction is provided. Especially compositions for release of the nicotine in the oral cavity can advantageously contain a buffer substance, i.e. compositions like snuff compositions.
Suitable buffering agents are typically those selected from the group consisting of acetates, glycinates, phosphates, glycerophosphates, citrates such as citrates of alkaline metals, carbonates, and hydrogen carbonates, and borates, or mixtures thereof. Especially, a carbonate, a hydrogen carbonate or a phosphate including a triphosphate is suitable as a buffer agent.
If present the one or more buffering agents are present in a concentration from about 0.5% w/w to about 5% w/w, such as, e.g., from about 0.75% w/w to about 4%, w/w, from about 0.75% w/w to about 3%, w/w or from about 1% w/w to about 2%, w/w.
In a specific embodiment, the concentration of the one or more buffering agents is from about 0.1% w/w to about 5% w/w, such as, e.g., from about 0.2% w/w to about 4% w/w, from about 0.3% w/w to about 4% w/w, from about 0.4% w/w to about 3% w/w, from about 0.5% w/w to about 2% w/w, from about 0.6% w/w to about 1% w/w or from about 0.7% w/w to about 0.9% w/w such as about 0.8% w/w.
Sweeteners—Flavouring Agents
In order to improve the sensory properties of the composition according to the invention one or more sweeteners or texture improves may be added, such as sugar alcohols including xylitol, sorbitol, maltitol and/or isomalt, or artificial sweeteners such as e.g. aspartame, acesulfame or saccharin.
The concentration of the one or more sweeteners, if present, is normally at least about 0.05% such as, e.g. from about 0.075% w/w to about 5% w/w or from about 5% to about 35% w/w, such as, e.g., from about 10% w/w to about 35% w/w, from about 15% w/w to about 35% w/w or from about 20% w/w to about 30% w/w. In an interesting embodiment the one or more sweeteners are present in a concentration from about 0.01% w/w to about 0.2% w/w, such as, e.g., from about 0.01% w/w to about 0.15% w/w, from about 0.02% w/w to about 0.12% w/w, from about 0.03% w/w to about 0.11% w/w, from about 0.04% w/w to about 0.1% w/w, from about 0.05% w/w to about 0.1% w/w, from about 0.06% w/w to about 0.1% w/w or from about 0.07% w/w to about 0.09% w/w such as about 0.08% w/w. As demonstrated in the examples herein a concentration of the one or more artificial sweeteners of about 0.08% gives good sensoric acceptance.
In order to improve the organoleptic properties of a composition according to the invention, the composition may include one or more flavouring agents, such as, e.g., menthol flavour, eucalyptus, mint flavour and/or L-menthol, normally present (total concentration of flavouring agents) in a concentration of from about 0.5% w/w to about 12% w/w, from about 1% w/w to about 10% w/w, from about 1.5% w/w to about 9% w/w or from about 2% w/w to about 8% w/w.
In a particular embodiment the flavour is mint flavour and the concentration of the one or more flavouring agents is from about 1% w/w to about 15% w/w, such as, e.g., from about 1% w/w to about 10% w/w, from about 1.5% w/w to about 8% w/w, from about 2% w/w to about 6% w/w or from about 3% w/w to about 5% w/w such as about 4% w/w. In a specific embodiment, the concentration of the one or more flavouring agents is about 4% w/w.
It is well-known that nicotine is subject to oxidation and accordingly, it may be advantageous to incorporate one or more anti-oxidants, such as, e.g., ascorbyl palmitate and/or sodium ascorbate, in a composition according to the invention.
The one or more anti-oxidants may be present in a concentration of from about 0.4% w/w to about 2.4% w/w, such as, e.g., from about 0.5% w/w to about 2.2% w/w, from about 0.6% w/w to about 2% w/w, from about 0.7% w/w to about 1.8% w/w or from about 0.8% w/w to about 1.6% w/w.
Specific Embodiments
In specific embodiments the invention relates to
A snuff composition comprising
A snuff composition comprising
A snuff composition comprising
i) a nicotine-cellulose combination containing from about 0.5 to about 10 mg of nicotine
A snuff composition comprising
A method of administering a snuff composition with a high release rate comprising the step of:
delivering a snuff composition comprising a carrier combined with nicotine, or a pharmaceutically acceptable salt, solvate, complex, or derivative thereof, wherein at least about 30% w/w of the total content of nicotine is released within 30 minutes when said composition is subjected to an in vitro dissolution test.
A method of making a snuff composition with a high release rate, comprising the step of: combining nicotine, or a pharmaceutically acceptable salt, solvate, complex, or derivative thereof, with a carrier, wherein at least about 30% w/w of the total content of nicotine is released within 30 minutes when said composition is subjected to an in vitro dissolution test.
All particulars and details mentioned above relating to the main aspect in general apply mutatis mutandis to the above mentioned specific embodiments.
The invention is further illustrated in the following figures and non-limiting examples.
In vitro Dissolution Test
The snuff compositions according to the invention are normally tested to fulfill specific requirements with respect to in vitro release of nicotine. A suitable in vitro test depends on the specific composition in question. In general, a person skilled in the art will find guidance as to how to choose a relevant dissolution test for a specific composition in the official monographs such as, e.g., the European Pharmacopoeia. Below are described suitable dissolution tests in case of snuff compositions.
Snuff
The following dissolution method for testing of the release of nicotine from snuff compositions was used.
The method describes in-vitro release of nicotine from snuff using UV detection. The released nicotine diffuses through a dialysis membrane into a stream of tempered phosphate buffer.
Equipment
Instrument Settings
Materials
Cut two pieces of silicon hoses, 150 and 35 cm long. Insert a 3 cm long hard plastic hose (o.d. 7 mm) in one end of the two ‘blood vessels’ for support. Cut a piece of dialysis membrane and pre-treat according to manufacturer. Thread the membrane through two 2.5 cm long silicon hose pieces (i.d. 6 mm). The supported ends of the blood vessels should be inserted approximately 3 cm into the membrane and secured with the two small silicon rings (See
Add 250 ml phosphate buffer [6] to the 250 ml beaker and add a magnetic bar. Place it in the water bath and start the heating and rotation. Connect the silicone hose to the secondary pump and place the longest part to the beaker. Place a pipette tip (1 ml) into the shorter end to work as a pressure restrictor. The hole in the tip may be expanded in order to adjust the back pressure. Prime the tubing with buffer.
Place the two tubings from the flow cell in the beaker. (See
Stop the flow and fold the membrane on the middle. Use a piece of paper to slide the membrane into the sample tube as far down as possible. Start the pump and carefully insert the snuff bag halfway down the sample tube between the membranes (see
Sampling
The concentrations of nicotine in the samples are calculated.
As an alternative method, USP basket method (in vitro dissolution of tablets) can be used employing 500 ml water as dissolution medium.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Nicotine was sorbed onto microcrystalline cellulose (MCC) as described in WO 2004/056363. Accordingly, in the present example 2.40 ml nicotine was dissolved in 25 ml ethanol (99.5%). 47.6 g MCC of type PH-102 was loaded into a high-speed mixer and the nicotine was slowly added. After vacuum drying of the obtained wetted mass a fine-grained, white powder of nicotine-microcrystalline cellulose carrier complex was obtained.
Nicotine was sorbed onto microcrystalline cellulose (MCC) to obtain nicotine-microcrystalline cellulose carrier complexes essentially as described above. The obtained nicotine-microcrystalline cellulose carrier complexes were mixed with the remaining ingredients to obtain the compositions E, F, G, H, I and J stated in the following table:
Nicotine was purchased from Siegfried, Switzerland, (batch no. 0338I006), Microcrystalline cellulose was purchased from FMC, Belgium (batch no. M301C), Peppermint powder flavour was purchased from Firmenich, Switzerland (batch no. JP05040527), Acesulfame potassium was purchased from L&P Food Ingredient, China (batch no. (ZD02035), Aspartame powder was purchased from NutraSweet, Switzerland (batch no. C000220), Sodium carbonate was purchased from Aldrich, Germany (batch no. A008729PI), Sodium hydrogen carbonate was purchased from Merck, Germany (batch no. K28409723047), Sodium triphosphate was purchased from Sigma, USA (supplied from Swedish Match Sweden).
150 mg of the compositions E-J, respectively, were filled into snuff bags made of a snuff bag material obtained from Swedish Match, Sweden (batch no. W-NR00217, RL-NR6). The snuff bag size used is similar to the present marketed dry snuff bags, i.e. as “Catch® dry”.
In vitro Release from Snuff Bag Compositions E, F, G, H, I and J
Measurement of in vitro release rates of nicotine from snuff bags were performed using an in vitro dissolution test developed at Swedish Match, Stockholm, and utilizing a plastic flow-chamber in a tube with buffer solution combined with UV detection on a spectrophotometer at 260 nm. The details are mentioned above under the heading “In vitro dissolution test”.
The in vitro release of nicotine from compositions E-J in percentage of the total content of nicotine are stated in the table below:
Furthermore, comparison studies of the in vitro release profiles of nicotine from snuff bags containing snuff compositions according to the present invention and already marketed snuff bags were performed. In
In
In vivo Uptake of Nicotine from Snuff Bag Containing Composition
A comparison study of the in vivo uptake of nicotine from the snuff product “General”, 4 mg Nicorette® chewing gum and a snuff bag comprising composition J was performed. Composition J contained 0.8% sodium hydrogen carbonate and 0.8% sodium carbonate. Blood samples were taken at 0, 5, 10, 15, 20, 30 and 40 minutes after application and the plasma concentrations of nicotine were determined by ABS laboratories, London, England. After addition of sodium hydroxide, the plasma samples were extracted with dichloroethane and nicotine was quantitatively determined by gas chromatography using a nitrogen/phosphorous detector. 5-methyl cotinine was used to internally standardize the procedure. The limit of quantification is 0.5 ng/ml.
The results are shown in
Furthermore, a pilot pharmacokinetic study (n=4) in which the in vivo uptake of nicotine from snuff compositions G, J and I were compared to the in vivo uptake from Nicorette® 4 mg chewing gum. The result shown in
Residual Amounts of Nicotine in Snuff Bags Comprising Snuff Compositions G, I and J —in vitro vs. in vivo
Snuff bags comprising either of compositions G, I or J were subjected to either the above-mentioned in vitro dissolution test employing USP basket apparatus or the above-mentioned pilot pharmacokinetic assay in 30 minutes. Subsequently, the residual nicotine content in the snuff bags was investigated using a dissolution bath combined with a UV-detection on a spectrophotometer at 260 nm. The dissolution was determined according to the dissolution method for tablets USP (basket) using 500 ml water as dissolution medium and a temperature of 37° C.
The results are shown in the following table:
It follows from the figures in the above table, that the residual amount of nicotine in the snuff bags after 30 minutes of in vitro dissolution test is between 50% and 57% of the initial content of nicotine, i.e. between 43% and 50% of the nicotine has been released in the in vitro dissolution test. It further follows that the residual amount of nicotine in the snuff bags after 30 minutes of the in vivo pharmacokinetic study, is between 45% and 50% of the initial content of nicotine, i.e. between 45% and 50% of the nicotine has been absorbed in the bloodstream.
Comparison of Nicorette 4 mg gum with MCC-nicotine Containing Snuff Composition with 5 mg Nicotine
Single dose pharmacokinetics was studied in four subjects in comparison to Nicorette 4 mg gum (
The bioavailability of nicotine from the nicotine snuff composition appears higher that that seen for the Nicorefte® composition even if the different in dosage is taken into account.
References
All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, and composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the present invention, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present invention. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.
| Number | Date | Country | Kind |
|---|---|---|---|
| PA 2006 00375 | Mar 2006 | DK | national |
| PA 2006 00376 | Mar 2006 | DK | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2007/002343 | 3/16/2007 | WO | 00 | 6/16/2009 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2007/104573 | 9/20/2007 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 865026 | Ellis | Sep 1907 | A |
| 940521 | Endicott | Nov 1909 | A |
| 3777029 | Magid | Dec 1973 | A |
| 3845217 | Ferno et al. | Oct 1974 | A |
| 3877468 | Lichtneckert et al. | Apr 1975 | A |
| 3901248 | Lichtneckert et al. | Aug 1975 | A |
| 4317837 | Kehoe et al. | Mar 1982 | A |
| 4579858 | Ferno et al. | Apr 1986 | A |
| 4593572 | Linley, Jr. | Jun 1986 | A |
| 4655231 | Ray et al. | Apr 1987 | A |
| 4674491 | Brugger et al. | Jun 1987 | A |
| 4696315 | Summers | Sep 1987 | A |
| 4806356 | Shaw | Feb 1989 | A |
| 4817640 | Summers | Apr 1989 | A |
| 4835162 | Abood | May 1989 | A |
| 4907605 | Ray et al. | Mar 1990 | A |
| 4933188 | Cherukuri et al. | Jun 1990 | A |
| 4945929 | Egilmex et al. | Aug 1990 | A |
| 4967733 | Rousseau et al. | Nov 1990 | A |
| 4967773 | Shaw | Nov 1990 | A |
| 4971079 | Talapin et al. | Nov 1990 | A |
| 5069904 | Masterson | Dec 1991 | A |
| 5077104 | Hunt et al. | Dec 1991 | A |
| 5135753 | Baker et al. | Aug 1992 | A |
| 5154927 | Song et al. | Oct 1992 | A |
| 5167242 | Turner et al. | Dec 1992 | A |
| 5198226 | MacFarlane et al. | Mar 1993 | A |
| 5268209 | Hunt et al. | Dec 1993 | A |
| 5284163 | Knudsen et al. | Feb 1994 | A |
| 5318523 | Lu et al. | Jun 1994 | A |
| 5326570 | Rudnic et al. | Jul 1994 | A |
| 5346589 | Braunstein et al. | Sep 1994 | A |
| 5362496 | Baker et al. | Nov 1994 | A |
| 5488962 | Perfetti | Feb 1996 | A |
| 5501858 | Fuisz | Mar 1996 | A |
| 5507278 | Karell | Apr 1996 | A |
| 5525351 | Dam et al. | Jun 1996 | A |
| 5543424 | Carlsson et al. | Aug 1996 | A |
| 5549906 | Santus et al. | Aug 1996 | A |
| 5573774 | Keenan | Nov 1996 | A |
| 5593684 | Baker et al. | Jan 1997 | A |
| 5599554 | Majeti | Feb 1997 | A |
| 5643905 | Moormann et al. | Jul 1997 | A |
| 5654003 | Fuisz et al. | Aug 1997 | A |
| 5656255 | Jones | Aug 1997 | A |
| 5662920 | Santus | Sep 1997 | A |
| 5692493 | Weinstein et al. | Dec 1997 | A |
| 5711961 | Reiner et al. | Jan 1998 | A |
| 5721257 | Baker et al. | Feb 1998 | A |
| 5733574 | Dam et al. | Mar 1998 | A |
| 5810018 | Monte | Sep 1998 | A |
| 5885645 | Wong et al. | Mar 1999 | A |
| 5935604 | Illum | Aug 1999 | A |
| 5939100 | Albrechtsen et al. | Aug 1999 | A |
| 5948422 | van Koutrik et al. | Sep 1999 | A |
| 5955098 | Dugger, III | Sep 1999 | A |
| 6024981 | Khankari et al. | Feb 2000 | A |
| 6062214 | Howlett | May 2000 | A |
| 6083531 | Humbert-Droz et al. | Jul 2000 | A |
| 6110495 | Dam et al. | Aug 2000 | A |
| 6129936 | Gustafsson et al. | Oct 2000 | A |
| 6183775 | Ventouras | Feb 2001 | B1 |
| 6190696 | Groenewoud | Feb 2001 | B1 |
| 6224904 | Rapp et al. | May 2001 | B1 |
| 6264981 | Zhang et al. | Jul 2001 | B1 |
| 6280761 | Santus | Aug 2001 | B1 |
| 6287596 | Murakami et al. | Sep 2001 | B1 |
| 6322806 | Ream et al. | Nov 2001 | B1 |
| 6322828 | Athanikar et al. | Nov 2001 | B1 |
| 6344222 | Cherukuri et al. | Feb 2002 | B1 |
| 6352986 | Hassan et al. | Mar 2002 | B1 |
| 6355265 | Ream et al. | Mar 2002 | B1 |
| 6358060 | Pinney et al. | Mar 2002 | B2 |
| 6358527 | Gilis et al. | Mar 2002 | B1 |
| 6426090 | Ream et al. | Jul 2002 | B1 |
| 6465003 | Ream et al. | Oct 2002 | B2 |
| 6551634 | Joergensen | Apr 2003 | B2 |
| 6558692 | Ream et al. | May 2003 | B2 |
| 6562372 | Yokoi et al. | May 2003 | B1 |
| 6586023 | Song et al. | Jul 2003 | B1 |
| 6599901 | Flohr et al. | Jul 2003 | B1 |
| 6602518 | Seielstad et al. | Aug 2003 | B2 |
| 6627234 | Johnson et al. | Sep 2003 | B1 |
| 6773716 | Ream et al. | Aug 2004 | B2 |
| 6790496 | Levander et al. | Sep 2004 | B1 |
| 6841557 | Anderson et al. | Jan 2005 | B2 |
| 6845777 | Pera | Jan 2005 | B2 |
| 6849286 | Bayerköhler et al. | Feb 2005 | B1 |
| 6849624 | Ballard et al. | Feb 2005 | B2 |
| 6855820 | Broom et al. | Feb 2005 | B2 |
| 6858624 | Hagen et al. | Feb 2005 | B2 |
| 6861434 | Stack | Mar 2005 | B2 |
| 6872405 | Takaishi et al. | Mar 2005 | B2 |
| 6893654 | Pinney et al. | May 2005 | B2 |
| 6932971 | Bachmann et al. | Aug 2005 | B2 |
| 6958143 | Choi et al. | Oct 2005 | B2 |
| 6958323 | Olivera et al. | Oct 2005 | B2 |
| 6960574 | Prokai | Nov 2005 | B2 |
| 6982089 | Tobinick | Jan 2006 | B2 |
| 7101579 | Athanikar et al. | Sep 2006 | B2 |
| 7163705 | Johnson et al. | Jan 2007 | B2 |
| 7208186 | Norman et al. | Apr 2007 | B2 |
| 20010016593 | Wilheimsen | Aug 2001 | A1 |
| 20010029959 | Burgard et al. | Oct 2001 | A1 |
| 20020009523 | Gustaesson | Jan 2002 | A1 |
| 20020010198 | Jerussi et al. | Jan 2002 | A1 |
| 20020015687 | Bellamy et al. | Feb 2002 | A1 |
| 20030077297 | Chen et al. | Apr 2003 | A1 |
| 20030082109 | Gorenstein | May 2003 | A1 |
| 20030124191 | Besse et al. | Jul 2003 | A1 |
| 20030152634 | Bodmeier | Aug 2003 | A1 |
| 20030180360 | Am Ende et al. | Sep 2003 | A1 |
| 20030224048 | Walling | Dec 2003 | A1 |
| 20040013752 | Wolfson | Jan 2004 | A1 |
| 20040096501 | Vaya et al. | May 2004 | A1 |
| 20040191322 | Hansson | Sep 2004 | A1 |
| 20040194793 | Lindell et al. | Oct 2004 | A1 |
| 20040247669 | Gin et al. | Dec 2004 | A1 |
| 20050009813 | Moormann et al. | Jan 2005 | A1 |
| 20050009882 | Farr | Jan 2005 | A1 |
| 20050013856 | Trivedi et al. | Jan 2005 | A1 |
| 20050020641 | Sellers et al. | Jan 2005 | A1 |
| 20050042173 | Besse et al. | Feb 2005 | A1 |
| 20050053665 | Ek et al. | Mar 2005 | A1 |
| 20050058609 | Nazeri | Mar 2005 | A1 |
| 20050089524 | Sanderson et al. | Apr 2005 | A1 |
| 20050100513 | Watkins et al. | May 2005 | A1 |
| 20050107397 | Galambos et al. | May 2005 | A1 |
| 20050118272 | Besse et al. | Jun 2005 | A1 |
| 20050123502 | Chan et al. | Jun 2005 | A1 |
| 20050129774 | Morein et al. | Jun 2005 | A1 |
| 20050136047 | Ennifar et al. | Jun 2005 | A1 |
| 20050182063 | Yohannes | Aug 2005 | A1 |
| 20050197343 | Gmeiner et al. | Sep 2005 | A1 |
| 20050222270 | Olney et al. | Oct 2005 | A1 |
| 20050227998 | Voelker | Oct 2005 | A1 |
| 20050260264 | Edgren et al. | Nov 2005 | A1 |
| 20050261289 | Flohr et al. | Nov 2005 | A1 |
| 20050277626 | Dinan et al. | Dec 2005 | A1 |
| 20050282823 | Breining et al. | Dec 2005 | A1 |
| 20060057207 | Ziegler et al. | Mar 2006 | A1 |
| 20060058328 | Bhatti et al. | Mar 2006 | A1 |
| 20060062835 | Weil | Mar 2006 | A1 |
| 20060084656 | Ziegler et al. | Apr 2006 | A1 |
| 20060099300 | Andersen et al. | May 2006 | A1 |
| 20060147498 | Jonsson et al. | Jul 2006 | A1 |
| 20060165842 | Andersen et al. | Jul 2006 | A1 |
| 20060171969 | Macelloni et al. | Aug 2006 | A1 |
| 20060204451 | Salini | Sep 2006 | A1 |
| 20060240143 | Andersen et al. | Oct 2006 | A1 |
| 20060246174 | Andersen et al. | Nov 2006 | A1 |
| 20060252773 | Ceci | Nov 2006 | A1 |
| 20060275344 | Mody et al. | Dec 2006 | A1 |
| 20060276551 | Shytle et al. | Dec 2006 | A1 |
| 20070014887 | Cherukuri et al. | Jan 2007 | A1 |
| 20070071806 | McCarty | Mar 2007 | A1 |
| 20070134169 | Rabinoff | Jun 2007 | A1 |
| 20080020050 | Chau et al. | Jan 2008 | A1 |
| 20080124283 | Andersen | May 2008 | A1 |
| 20080131508 | Agarwal et al. | Jun 2008 | A1 |
| 20080138398 | Gonda | Jun 2008 | A1 |
| 20080138399 | Gonda | Jun 2008 | A1 |
| 20080138423 | Gonda | Jun 2008 | A1 |
| 20080286340 | Andersson et al. | Nov 2008 | A1 |
| 20080286341 | Andersson et al. | Nov 2008 | A1 |
| 20080292683 | Sanghvi et al. | Nov 2008 | A1 |
| 20080317863 | Nystrom et al. | Dec 2008 | A1 |
| 20090081291 | Gin et al. | Mar 2009 | A1 |
| 20090098192 | Fuisz | Apr 2009 | A1 |
| 20100004294 | Axelsson et al. | Jan 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 1089834 | Jul 1994 | CN |
| 1383814 | Dec 2002 | CN |
| 1511550 | Jul 2004 | CN |
| 1557177 | Dec 2004 | CN |
| 23 13 996 | Oct 1974 | DE |
| 2313996 | Oct 1974 | DE |
| 3241437 | May 1984 | DE |
| 2 05 133 | Dec 1986 | EP |
| 2 15 682 | Mar 1987 | EP |
| 3 77 520 | Jul 1990 | EP |
| 4 72 428 | Feb 1992 | EP |
| 05 57 129 | Aug 1993 | EP |
| 5 70 327 | Nov 1993 | EP |
| 07 45 380 | Dec 1996 | EP |
| 09 16 339 | May 1999 | EP |
| 2147652 | Mar 1973 | FR |
| 2467604 | Apr 1981 | FR |
| 2 608 156 | Jun 1988 | FR |
| 2698268 | May 1994 | FR |
| 2788982 | Aug 2000 | FR |
| 2792200 | Oct 2000 | FR |
| 1528391 | Oct 1978 | GB |
| 2030862 | Apr 1980 | GB |
| 2 227 659 | Aug 1990 | GB |
| 2255892 | Nov 1992 | GB |
| 2289204 | Nov 1995 | GB |
| 2308992 | Jul 1997 | GB |
| 2 393 392 | Mar 2004 | GB |
| 2393392 | Mar 2004 | GB |
| 2005082587 | Mar 2005 | JP |
| 2005103113 | Apr 2005 | JP |
| 2005320342 | Nov 2005 | JP |
| 2029474 | Feb 1995 | RU |
| 1232260 | May 1986 | SU |
| 1268141 | Nov 1986 | SU |
| WO 8803803 | Jun 1988 | WO |
| WO9101132 | Feb 1991 | WO |
| WO9104757 | Apr 1991 | WO |
| WO9106288 | May 1991 | WO |
| WO9109599 | Jul 1991 | WO |
| WO9109731 | Jul 1991 | WO |
| WO9503050 | Feb 1995 | WO |
| WO9520411 | Aug 1995 | WO |
| WO9702273 | Jan 1997 | WO |
| WO9710162 | Mar 1997 | WO |
| WO9742941 | Nov 1997 | WO |
| WO9915171 | Apr 1999 | WO |
| WO9965550 | Dec 1999 | WO |
| WO0019977 | Apr 2000 | WO |
| WO0038686 | Jul 2000 | WO |
| WO0045795 | Aug 2000 | WO |
| WO0056281 | Sep 2000 | WO |
| WO0137814 | May 2001 | WO |
| WO02102357 | Dec 2002 | WO |
| WO03013719 | Feb 2003 | WO |
| WO03002446 | Jul 2003 | WO |
| WO03053175 | Jul 2003 | WO |
| WO-03053175 | Jul 2003 | WO |
| WO03055486 | Jul 2003 | WO |
| WO03061399 | Jul 2003 | WO |
| WO03101454 | Dec 2003 | WO |
| WO 2004004480 | Jan 2004 | WO |
| WO 2004056219 | Jul 2004 | WO |
| WO-2004056219 | Jul 2004 | WO |
| WO 2004056363 | Jul 2004 | WO |
| WO-2004056363 | Jul 2004 | WO |
| WO 2004064811 | Aug 2004 | WO |
| WO-2004064811 | Aug 2004 | WO |
| WO-2005023227 | Mar 2005 | WO |
| WO 2005034968 | Apr 2005 | WO |
| WO 2005040338 | May 2005 | WO |
| WO 2005053691 | Jun 2005 | WO |
| WO 2005115180 | Dec 2005 | WO |
| WO-2005115180 | Dec 2005 | WO |
| WO 2006028344 | Mar 2006 | WO |
| WO 2006037418 | Apr 2006 | WO |
| WO 2006115202 | Nov 2006 | WO |
| WO 2007006117 | Jan 2007 | WO |
| Entry |
|---|
| Nasr et al., In Vitro Study of Nicotine Release from Smokeless Tobacco, Journal of AOAC International, vol. 81, No. 3, 1998. |
| European Board of Appeal Decision of Technical Board: “Interlocutory Decision of the Opposition Division of the European Patent Office Posted on Jul. 12, 2010 Concerning Maintenance of the European U.S. Pat. No. 1578422 in Amended Form,” Decision dated Jan. 27, 2015. pp. 1-31. |
| Ullman's Encyclopedia of Industrial Chemistry, 5th Revised Ed. (1991), vol. A 19, Ed. Elvers, B., Hawkins, S. and Schulz, G. |
| http://www.fmc.com/—pages for Avicel products and MCC/Cellulose gel. |
| http://en.wikipedia.mg/wiki/Excipient. |
| Axelsson et al., “The Anti-smoking Effect of chewing gum with nicotine of high and low bioavailability”; 3rd World Conference on Smoking and Health, New York, 1975. |
| Jenkusky, “Use of Nicotine Patches for Schizophrenic Patients,” Am J. Psychiatry, 150:12, Dec. 1993. P. 1899. |
| Lihong et al., “Preparation and Pharmaceutical Study of Nicotine Sustained Release Tablet,” The Journal of Pharmaceutical Practice, vol. 19, 2001, No. 4, pp. 288-289. |
| Mihranyan et al., “Sorption of nicotine to cellulose powders”, European Journal Pharmaceutical Sciences; 2004; 279-286; 22(4). |
| Mihranyan, “Engineering of Native Cellulose Structure for Pharmaceutical Applications, Influence of Cellulose Crystallinity Index, Surgace Area and Pore Volume on Sorption Phenomena”, ACTA Universitatis Upsaliensis Uppsala; 2005; 1-57. |
| Molander el al., “Pharmacokinetic investigation of a nicotine sublingual tablet”, .Eur. J. Clin. Pharmacol. 2001; 813-9; vol. 56(11). |
| Morjaria et al., “In Vitro Release of Nicotine From Chewing Gum Formulations”, Dissolution Technologies; May 2004; 12-15; vol. 11(2). |
| Nasr et al., “In Vitro Study of Nicotine Release From Smokeless Tobacco,” J. AOAC International, 1998, vol. 81, No. 3. pp. 540-543. |
| Thomas et al., “Transdermal Nicotine ad Maintenance Therapy for Ulcerative Colitis,” The New England Journal of Medicine, Apr. 13, 1995. |
| Quik, “Smoking, Nicotine and Parkinson's Disease,” Trends in Neurosciences, vol. 27, No. 9, 2004. |
| Sahakian et al., “Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients and Dementia of the Alzheimer Type,” Dept. of Experimental Psychology, University of Cambridge, U.K. Drug Development Research, vol. 31, pp. 80-88, 1994. |
| Number | Date | Country | |
|---|---|---|---|
| 20090293895 A1 | Dec 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60782903 | Mar 2006 | US | |
| 60782977 | Mar 2006 | US |
